Process for Making Beta 3 Agonists and Intermediates
US-2020031838-A1 · Jan 30, 2020 · US
US10696681B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10696681-B2 |
| Application number | US-201916298467-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 11, 2019 |
| Priority date | Mar 15, 2013 |
| Publication date | Jun 30, 2020 |
| Grant date | Jun 30, 2020 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The application is directed to efficient and economical processes as described in more detail below for the preparation of the beta 3 agonists of the formula of I-7 and intermediate compounds that can be used for making these agonists. The present disclosure relates to a process for making beta-3 agonists and intermediates using ketoreductase (KRED) biocatalyst enzymes and methods of using the biocatalysts.
Opening claim text (preview).
What is claimed is: 1. A crystalline form of the HCl salt of Compound I-5(b), wherein Compound I-5(b) has the chemical structure: and wherein the crystalline form is characterized by an XRPD pattern having 2θ peaks at about 8.6°, 13.5°, and 16.7° 20.9°, and 22.7°. 2. The crystalline form of claim 1 , wherein the crystalline form is characterized by an XRPD pattern having 2θ peaks at about 8.6°, 12.9°, 13.5°, 16.7°, 20.9°, 22.7°, and 24.4°. 3. The crystalline form of claim 1 , wherein the crystalline form is characterized by an XRPD pattern having 2θ peaks at about 4.2°, 8.6°, 12.9°, 13.5°, 16.7°, 20.9°, 22.7°, 24.4°, 24.7°, and 28.2°. 4. The crystalline form of claim 1 , wherein the crystalline form is characterized by an XRPD pattern as shown in FIG. 1 . 5. The crystalline form of claim 1 , wherein the crystalline form is characterized by an XRPD pattern having the following reflections with the d-spacing Position [°2 Theta] d-spacing [Å] 4.2174 20.95196 8.5827 10.3028 12.9282 6.84784 13.5177 6.55051 16.65 5.32461 20.9425 4.24193 22.6974 3.91777 24.363 3.65356 24.6986 3.60468 28.1911 3.16555.
containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton · CPC title
Ortho-condensed systems · CPC title
with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms · CPC title
Oxygen or sulfur atoms · CPC title
Nitrogen as only ring hetero atom · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.